Likelihood of Approval and Phase Transition Success Rate Model – Fosfomycin Disodium in Pyelonephritis
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Fosfomycin Disodium in Pyelonephritis report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Fosfomycin Disodium in Pyelonephritis Drug Details:
Fosfomycin disodium is under development for the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis, suspected infection or peri-operative prophylaxis in pediatrics, pediatric acute lymphoblastic leukemia and other unspecified infections. It is formulated as powder and administered through intravenous route. The drug candidate inhibits cell wall synthesis. The drug candidate is a broad-spectrum intravenous phosphonic acid derivative and the only member of the epoxide antibiotic class. The drug candidate inhibits the PG and thereby aid in the treatment of the condition. It was also under development for complicated intra-abdominal infections (cIAI), acute bacterial skin and skin structure infections(ABSSI) and hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP).
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Fosfomycin Disodium LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports